Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

BACKGROUND: In pre-clinical studies, the anti-tumor activity of T-DM1 was enhanced when combined with taxanes or pertuzumab. This phase 1b/2a study evaluated the safety/tolerability of T-DM1 + paclitaxel ± pertuzumab in HER2-positive advanced breast cancer. METHODS: In phase 1b (n = 60), a 3 + 3 dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Krop, Ian E., Modi, Shanu, LoRusso, Patricia M., Pegram, Mark, Guardino, Ellie, Althaus, Betsy, Lu, Dan, Strasak, Alexander, Elias, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791863/
https://www.ncbi.nlm.nih.gov/pubmed/26979312
http://dx.doi.org/10.1186/s13058-016-0691-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791863/
https://www.ncbi.nlm.nih.gov/pubmed/26979312
http://dx.doi.org/10.1186/s13058-016-0691-7

Ejemplares similares